Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q4 FY2021 Earnings Presentation
22 slides from Lincoln Pharmaceuticals's earnings presentation, 2021
Slide 1: Q4 FY2021 Earnings Presentation
Q4 FY2021 Earnings Presentation GROWING IS COMMITMENT. WE POSSESS. P H A R M A C E U T IC A L S LT D . H E ALTH C A R E F O R A L L www.lincolnpharma.com 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfo
Slide 3: Corporate Overview
CORPORATE OVERVIEW BACKGROUND PRODUCT PORTFOLIO MANUFACTURING EXPORTS • Established in the year • 1700 registered products and • Manufacturing facility at • Exports to 60 plus countries 1979, Lincoln Pharma has another 700 in pipeline Khatraj in Ahmedabad, Gujarat currently & plans to expand to deve
Slide 4: Q4 & FY21 Performance & Roadmap
Q4 & FY21 Performance & Roadmap • Our company is growing from strength to strength and delivering robust operational and financial performance while maintaining healthy growth in revenue, margins and profitability and expects to continue the growth momentum in the coming years. • Revenue for the FY
Slide 5: Q4FY21 Results
Q4FY21 Results NET REVENUE EBITDA PAT 38.9% 12.6 -0.7% 17.78 41.6% 12.8 82.7 82.1 8.9 Q4FY20 Q4FY21 Q4FY20 Q4FY21 Q4FY20 Q4FY21 Q4 FY2021 Earnings Presentation Fig (Rs. Cr) 5
Slide 6: Performance – Focused Therapeutic Areas
Performance – Focused Therapeutic Areas Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 25.9% 31.9% Respiratory Systems 23.1% Therapeutic Area 33.7% 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones FY21 FY20 13% 15% Musculo-Skeletal System 8.4% 14% 8.7% Parasitol
Slide 7: Performance Overview
Performance Overview Consolidated Financial Performance Q4 Y-o-Y Q3 Q-o-Q Full Year Y-o-Y Particulars (mn.) FY2021 FY2020 Growth (%) FY2021 Growth (%) FY2021 FY2020 Growth (%) Net Revenue 821 827 -0.7% 1,155 -28.9% 4,299 3,975 8.1% EBITDA 177 128 38.3% 207 -14.5% 928 766 21.1% Margin (%) 21.6% 15.5%
Slide 8: About - Lincoln Pharmaceuticals Ltd
About - Lincoln Pharmaceuticals Ltd Providing Affordable and Innovative medicines for healthier lives. VISION To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging Strategic alliances both domestically and internationally. MISSION 1. Focused on delive
Slide 9: Key Milestones
Key Milestones 1979 1984-85 1992 1995-96 Lincoln was incorporated & Received WHO – GMP for plant / Converted in to a Public Limited commences operations as a Launched IPO & Listed on BSE production unit Company Partnership Firm 2015-16 2016-17 2000 2010-11 Listed on NSE Launched 3 products which are
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap • Pollution Control Board granted permission for setting up API Unit CAPEX • Civil Work for the Cephalosporin Plant is going on and it will complete soon. Total Capex estimated is Rs.40-45 crore. • Export Network to increase to 90+ Countries from 60 curre
Slide 11: Lincoln Pharmaceuticals Ltd - Financial Overview
Lincoln Pharmaceuticals Ltd - Financial Overview Year Revenue EBITDA PAT EPS Share Price FY 21 424 92 62 31.11 225 FY 11 189 13 6 4.51 35 10 Yrs CAGR 8.42% 21.61% 26.31% 21.33% 20.45% Book Value (Per Share) Market Cap (Rs. Cr) Net Debt (Rs. Cr) 472 188 450 420 425 157 108 108 135 71.1 112 268 96 -7.
Slide 12: Business Revenue Mix
Business Revenue Mix Particular (Rs. cr) FY 2013 (%) FY 2017 (%) FY 2021 (%) Domestic Sales 145.03 74.5% 246.46 67.4% 146.85 35.27% Exports 49.67 25.5% 119.27 32.6% 269.56 64.73% FY13 FY17 25.5 FY21 32.6 35.3 64.7 67.4 74.5 Exports Domestic Exports Domestic Exports Domestic Q4 FY2021 Earnings Presen
Slide 13: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Africa: Asia : America : Angola, Benin, Botswana, Burkina Afghanistan, Armenia, Azerbaijan, Bolivia, Chile, Costa Faso, Burundi, Cam
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced as First Time in India Anti-fungal vaginal spray Diclofenac rectal spray Sildenafil oral spray Ondansetron Hydrochloride Oral Spray (DOMI-UP) Paracetamol 1000mg Programmed Release Tablet (PA-12) Micronized Progesterone Vaginal Spray (PR
Slide 15: Innovations - Lincoln Pharma
Innovations - Lincoln Pharma Q4 FY2021 Earnings Presentation 15
Slide 16: Product Range - Lincoln Pharma
Product Range - Lincoln Pharma Q4 FY2021 Earnings Presentation 16
Slide 17: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-malarial Anti-viral/ Anti- Otology / Anti-o
Slide 18: Best in Class Facilities
Best in Class Facilities Certifications: EU-GMP, WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption; 1MW Solar Roof installed Dosage Forms Produced at Unit 1 Dosage Forms Produce
Slide 19: Financial Highlights
Financial Highlights Revenue EBITDA 93 424 67 66 386 53 47 360 361 366 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 PAT Net Worth 376 62 313.1 51 269.3 49 224.5 35 192.6 28 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 Q4 FY2021 Ea
Slide 20: Profitability Ratios
Profitability Ratios EBITDA Margin PAT Margin 18% 21% 13.4% 14.6% 17% 13.2% 15% 13% 9.7% 7.8% FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 ROCE RONW 22.0% 22.1% 18.3% 21.0% 20.5% 17.0% 16.3% 17.5% 15.0% 12.7% FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018
Slide 21: Shareholding Information
Shareholding Information Mar 2021 March 2020 Investor Category No. of No. of Shares % Holding No. of No. of Shares % Holding Shareholders Held Shareholders Held Promoter Group 30 74,51,904 37.26% 30 64,71,379 32.36 Public Holding 21,385 1,25,48,096 62.74% 15,138 1,35,28,621 67.29 Total 21,415 2,00,0
Slide 22: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h, Satyam Complex, Science City Road, Sol, Ahmedabad — 380 060, Gujarat, INDIA Phone: +91-79-41078000 Fax +91-79-41078062 E-mail: info@lincoinpharma.com Web: www.lincoinpharma.com CIN: 124230GJ1995PLC024288 _— K) ‘CFO. Lincoln Pharmaceuticals Ltd LINCOLN darshit@linc
Lincoln Pharmaceuticals — Q4 FY2021 Earnings Presentation on 6ix